Log in to search using one of your social media accounts:

 

Is There a Standard for Surgical Therapy of HCC? Is There a Standard for Surgical Therapy of HCC?
This study compared different guidelines regarding indication for resection and transplantation in patients with hepatocellular carcinoma, with and without underlying cirrhosis. Is there a consensus?BMJ Open Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Drinks industry accused of downplaying 'alcohol-cancer risk'
Conclusion This qualitative analysis aimed to determine the accuracy of health information circulated by the alcohol industry on the links between alcohol and cancer. It found the industry and affiliated organisations use three main approaches: denial of the link between alcohol and cancer misinterpretation of the risk distraction by focusing on other risk factors This analysis highlights how these strategies could be detrimental to public health. Of course, it's possible, given this data was collected in 2016, that some of the websites and documents analysed by the researchers have since been updated. Regardless, the...
Source: NHS News Feed - September 8, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Statins slash the risk of death from cirrhosis by half
Researchers from the University Hospital of Hvidovre in Denmark found statins reduce the risk of dying from the alcohol-related disorder by 43 per cent but doctors are reluctant to prescribe them. (Source: the Mail online | Health)
Source: the Mail online | Health - September 7, 2017 Category: Consumer Health News Source Type: news

Cirrhosis
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 31, 2017 Category: General Medicine Source Type: news

Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis
An eight-week regimen containing grazoprevir-ruzasvir-uprifosbuvir appears to be effective for treating hepatitis C virus (HCV) infection in patients with or without cirrhosis, according to findings from a pair of randomized phase 2 open-label trials.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 21, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Alcohol warning: THIS trendy spice can protect you from liver disease caused by drinking
ALCOHOL consumed in large amounts is the main cause in the Western world of liver disease, which includes fatty liver, alcoholic hepatitis, and chronic hepatitis with liver fibrosis or cirrhosis. However, a popular spice may provide a beneficial effect if you ’ve overdone the drinking. (Source: Daily Express - Health)
Source: Daily Express - Health - August 15, 2017 Category: Consumer Health News Source Type: news

TRIF-dependent Toll-like receptor signaling suppresses Scd1 transcription in hepatocytes and prevents diet-induced hepatic steatosis
Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases that ranges in severity from hepatic steatosis to steatohepatitis, the latter of which is a major predisposing factor for liver cirrhosis and cancer. Toll-like receptor (TLR) signaling, which is critical for innate immunity, is generally believed to aggravate disease progression by inducing inflammation. Unexpectedly, we found that deficiency in TIR domain–containing adaptor-inducing interferon-β (TRIF), a cytosolic adaptor that transduces some TLR signals, worsened hepatic steatosis induced by a high-fat diet (HFD) and that such exacerbati...
Source: Signal Transduction Knowledge Environment - August 8, 2017 Category: Science Authors: Chen, J., Li, J., Yiu, J. H. C., Lam, J. K. W., Wong, C.-M., Dorweiler, B., Xu, A., Woo, C. W. Tags: STKE Research Articles Source Type: news

FDA OKs 8-Week Mavyret for Hepatitis C FDA OKs 8-Week Mavyret for Hepatitis C
Glecaprevir/pibrentasvir is the first HCV treatment of this duration approved for genotypes 1 through 6 in previously untreated adults without cirrhosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 3, 2017 Category: Consumer Health News Tags: Gastroenterology News Alert Source Type: news

FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C
August 3, 2017 -- The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 3, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Mavyret for Hepatitis C
The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis. Mavyret is also approved for adult patients with HCV genotype 1 infection who have been previously treated with a regimen either containing an NS5A inhibitor or an NS3/4A protease inhibitor but not both. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 3, 2017 Category: American Health Source Type: news

GI Bleeding in Cirrhosis Patients With CAD and Cardiac Stents GI Bleeding in Cirrhosis Patients With CAD and Cardiac Stents
Cirrhotic patients often have varices and coagulopathy. Is it safe to treat these patients with dual antiplatelet therapy after cardiac stenting?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Gore touts reduced portal hypertension, complications in Viatorr Tips trial
W.L. Gore & Associates today released preliminary data from a trial of its Viatorr Tips endoprosthesis with controlled expansion, touting reduced portal hypertension treatment complications when compared to the company’s legacy Tips device and bare metal stents. Data from the study was presented at The International Liver Congress 2017 in Amsterdam, the Flagstaff, Ariz.-based company said. Preliminary data from the trial, which has 21 patients currently and is still enrolling, also indicated a reduction in hospital admissions from cirrhosis-related complications, including refractory ascites and sepsis, when the ...
Source: Mass Device - August 1, 2017 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials Stent Grafts Stents Vascular W.L. Gore & Associates Source Type: news

Liver disease and alcohol: How YOU could find out if you have symptomless disease
LIVER disease and cirrhosis - can increase the risk of cancer and can be caused by drinking too much alcohol. (Source: Daily Express - Health)
Source: Daily Express - Health - July 31, 2017 Category: Consumer Health News Source Type: news

Combo Tx Fares Well in HIV-Positive Patients with HCV (CME/CE)
(MedPage Today) -- Sustained response in all HIV-positive patients without cirrhosis (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - July 26, 2017 Category: Consumer Health News Source Type: news

FDA approves Vosevi for Hepatitis C
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs - sofosbuvir and velpatasvir - and a new drug, voxilaprevir. (Source: World Pharma News)
Source: World Pharma News - July 19, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Vosevi (sofosbuvir, velpatasvir and voxilaprevir) for Hepatitis C
July 18, 2017 -- The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2017 Category: Drugs & Pharmacology Source Type: news

FDA approves Vosevi for Hepatitis C
The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 18, 2017 Category: American Health Source Type: news

Liver damage and alcohol: How do you know if you have symptomless cirrhosis?
CIRRHOSIS - is long-term liver damage that can eventually lead to liver failure and even increase the risk of cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - July 12, 2017 Category: Consumer Health News Source Type: news

The Link Between Cirrhosis and Stroke: New Findings The Link Between Cirrhosis and Stroke: New Findings
Stroke incidence in patients with cirrhosis was double that of those without cirrhosis. Several factors probably explain why.Medscape Neurology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery Viewpoint Source Type: news

DAAs for Chronic HCV in a Population Aged 65 Years and Older DAAs for Chronic HCV in a Population Aged 65 Years and Older
Are direct-acting antivirals safe and effective in elderly patients with HCV-related advanced fibrosis or cirrhosis?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Hepatitis B jab to be added to immunisations of babies born in UK
Babies born from the 1 August will be offered new “hexavalent” jab in effort to clamp down on infections that cause cirrhosis and liver cancerAll babies born in the UK will receive the hepatitis B jab as part of their routine immunisations from the autumn in an effort to drive down viral infections that cause cirrhosis and liver cancer.The hepatitis B vaccine is to be added to the 5-in-1 jab that is already given to babies across the UK to protect them from diphtheria, tetanus, whooping cough, polio and bacterial infections known as Hib, or haemophilus influenzae type b, health officials said.Continue reading.....
Source: Guardian Unlimited Science - July 9, 2017 Category: Science Authors: Ian Sample Science editor Tags: Hepatitis B Science Society Children UK news Source Type: news

Statins May Curb Progression of Chronic Liver Disease Statins May Curb Progression of Chronic Liver Disease
Statins may slow the progression of hepatic fibrosis, prevent cirrhosis-related hepatic decompensation and reduce all-cause mortality in patients with chronic liver disease - but the evidence is low, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Relatives of people with fatty liver cirrhosis also at risk
(Reuters Health) - If a parent or sibling has cirrhosis due to non-alcoholic fatty liver disease, a person's odds of having liver scarring are more than 12 times higher than for people without close relatives who have this condition, a small study finds. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Case Report: Hyperammonemia to Be Considered in Cirrhosis Setting
Authors describe case of 58 - year - old man who received blood obtained 17, 20 days earlier (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 14, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Gastroenterology, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Journal, Source Type: news

Antiviral therapy is effective in fighting hepatitis C | Letters
The Cochrane analysis casting doubt on this life-saving therapy is flawed and may deter patients from seeking it, say clinicians and scientistsWe are clinicians and scientists who have studied and treated patients with chronic hepatitis C virus infection over many years and patient groups that represent those affected by hepatitis C. We write in response to your article on the effectiveness of antiviral therapy (Hepatitis ‘wonder drug’ may be clinically ineffective, say experts, 9 June). The Cochrane review that you highlight analysed clinical trials, which are by nature short term, where the sole purpose was t...
Source: Guardian Unlimited Science - June 13, 2017 Category: Science Authors: Letters Tags: Hepatitis C Health Pharmaceuticals industry Medical research Drugs Business Science UK news Society Source Type: news

Cirrhosis Tied to Increased Stroke Risk (CME/CE)
(MedPage Today) -- Strongest association seen with subarachnoid and intracerebral hemorrhage (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 6, 2017 Category: Gastroenterology Source Type: news

Liver disease: Deadly form of the condition can also increase risk of stroke
LIVER damage can cause cirrhosis where the liver stops functioning properly. (Source: Daily Express - Health)
Source: Daily Express - Health - June 6, 2017 Category: Consumer Health News Source Type: news

Take a coffee or tea break to protect your liver
Chronic liver diseases rank as the 12th cause of death worldwide and many of these disorders are associated with unhealthy lifestyles. Conversely, a healthier lifestyle can help prevent or reverse liver disease. Liver-related mortality is closely related to the development of cirrhosis, the final consequence of progressive fibrosis, i.e. scarring of the liver resulting from chronic inflammation. According to a new study published in the Journal of Hepatology, researchers found that drinking coffee and herbal tea may protect against liver fibrosis, estimated as the degree of liver stiffness, which is high in extensive scarr...
Source: World Pharma News - June 6, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Cirrhosis Could Raise Stroke Risk
Title: Cirrhosis Could Raise Stroke RiskCategory: Health NewsCreated: 6/5/2017 12:00:00 AMLast Editorial Review: 6/6/2017 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - June 6, 2017 Category: Cardiology Source Type: news

Cirrhosis Tied to Stroke Risk (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Cirrhosis is associated with increased risk for stroke in older adults, according to a JAMA … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 5, 2017 Category: Primary Care Source Type: news

Study: Cirrhosis may increase risk for stroke
Cirrhosis -- a stiffening of liver tissue often tied to excessive drinking of alcohol -- may also raise an older person's odds for a stroke, a new study says. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 5, 2017 Category: Consumer Health News Source Type: news

Cirrhosis Could Raise Stroke Risk
Average yearly rate of the attacks doubled in people with the liver disease, study found Source: HealthDay Related MedlinePlus Pages: Cirrhosis, Stroke (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - June 5, 2017 Category: Consumer Health News Source Type: news

Cirrhosis Could Raise Stroke Risk
MONDAY, June 5, 2017 -- Cirrhosis -- a stiffening of liver tissue that's often tied to excessive drinking of alcohol -- may also raise an older person's odds for a stroke, a new study suggests. " In a nationally representative sample of elderly... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 5, 2017 Category: General Medicine Source Type: news

Ocera doses first patient in Phase IIa trial of OCR-002 to treat cirrhosis
Ocera Therapeutics has started dosing patients in the Phase IIa part of its Phase I/IIa clinical trial of oral OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis. (Source: Drug Development Technology)
Source: Drug Development Technology - June 4, 2017 Category: Pharmaceuticals Source Type: news

Rwanda: Why Children Should Never Take Alcohol
[New Times] It was shocking to see a young boy, merely 16 years having deranged liver function. On examination and with investigations, he was found to have liver cirrhosis. The underlying cause for liver cirrhosis being alcohol, which he had consumed since five of age. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - May 29, 2017 Category: African Health Source Type: news

World's leading liver experts focus on continuing advancements in liver disease & transplantation
(Intermountain Medical Center) As the prevalence of liver disease continues to rise across the world, the growing number of people impacted by cirrhosis, liver cancer, and nonalcoholic fatty liver disease, is the focus of more than 1,700 of the world's leading liver disease experts. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - May 24, 2017 Category: Infectious Diseases Source Type: news

Intestinal fungi linked to worsening of alcoholic liver disease
Liver cirrhosis is the 12th leading cause of mortality worldwide, with approximately half of those deaths due to alcohol misuse. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 22, 2017 Category: American Health Source Type: news

Media Advisory: Intestinal fungi linked to worsening of alcoholic liver disease
 What A new study funded by the National Institute on Alcohol Abuse and Alcoholism is among the first to suggest that intestinal fungi may contribute to the development of alcoholic liver disease (ALD). ALD encompasses a broad range of liver diseases, from simple steatosis (fatty liver) to end-stage liver disease, or cirrhosis (liver cell death). Liver cirrhosis is the 12th leading cause of mortality worldwide, with approximately half of those deaths due to alcohol misuse.   (Source: NIAAA News)
Source: NIAAA News - May 22, 2017 Category: Addiction Authors: groa Source Type: news

Intestinal fungi worsen alcoholic liver disease
(University of California - San Diego) Liver cirrhosis is the 12th leading cause of mortality worldwide and approximately half of those deaths are due to alcohol abuse. Yet apart from alcohol abstinence, there are no specific treatments to reduce the severity of alcohol-associated liver disease. Researchers at University of California San Diego School of Medicine and J. Craig Venter Institute (JCVI) have linked intestinal fungi to increased risk of death for patients with alcohol-related liver disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 22, 2017 Category: International Medicine & Public Health Source Type: news

Primary biliary cirrhosis
(Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - May 16, 2017 Category: Consumer Health News Source Type: news

New pill spares women trauma of liver transplant
In the UK, 20,000 people – 90 per cent of them women – suffer from primary biliary cholangitis, also known as primary biliary cirrhosis (PBC). (Source: the Mail online | Health)
Source: the Mail online | Health - May 13, 2017 Category: Consumer Health News Source Type: news

Gene Variant Predicts Liver Recovery After HCV Cure (CME/CE)
(MedPage Today) -- Finding might help treatment options in decompensated cirrhosis (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 8, 2017 Category: Gastroenterology Source Type: news

Gene Variation Predicts Recovery in Decompensated Hep C Gene Variation Predicts Recovery in Decompensated Hep C
Genetic differences that are associated with recovery in patients with hepatitis C and decompensated cirrhosis who achieve a sustained virologic response could someday guide liver transplantation.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 7, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Study: Genetic markers may predict which HCV, cirrhosis patients improve with treatment
This study was presented at Digestive Disease Week ® (DDW) 2017, the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 6, 2017 Category: Global & Universal Source Type: news

Stool microbes predict advanced liver disease
Nonalcoholic fatty liver disease (NAFLD) -- a condition that can lead to liver cirrhosis and cancer -- isn't typically detected until well advanced. Even then, diagnosis requires a biopsy. To more easily detect NAFLD, researchers report that the microbial makeup of a patient's stool -- gut microbiome -- can be used to predict advanced NAFLD with 88 to 94 percent accuracy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 2, 2017 Category: Science Source Type: news

Managing Upper GI Bleeding Due to Portal Hypertension Managing Upper GI Bleeding Due to Portal Hypertension
Dr Rowan Zetterman examines new practice guidance for the diagnosis and management of patients with cirrhosis and portal hypertension.Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 27, 2017 Category: Gastroenterology Tags: Gastroenterology Expert Column Source Type: news

New System Detects Cirrhosis in Fatty Liver Disease New System Detects Cirrhosis in Fatty Liver Disease
With up to 40% of patients in primary care in the US and Europe affected by fatty liver disease, identifying who will develop fibrosis or cirrhosis is a challenge, but a new strategy appears to help.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2017 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Long-Term Albumin Tx Ups Survival in Liver Failure (CME/CE)
(MedPage Today) -- Patients with decompensated cirrhosis also report better quality of life (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - April 25, 2017 Category: Gastroenterology Source Type: news

Sofosbuvir Plus an NS5A Inhibitor for HCV GT3 and Cirrhosis Sofosbuvir Plus an NS5A Inhibitor for HCV GT3 and Cirrhosis
This study evaluated the efficacy of regimens of SOF plus an NS5A inhibitor with or without RBV in this group.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2017 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news